Data from progranulin-deficient mouse models indicates that progranulin-boosting therapeutics can correct behavioral, biochemical, and neuropathological abnormalities even after onset, but initiating treatment after symptoms emerge would be limited by the fact that FTD-GRN progresses rapidly once it becomes symptomatic. Here, GRN is linked to frontotemporal dementia.